Clinical Trial: NCT06629779
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Status:
RECRUITINGPhase:
Phase 3| Lead Sponsor: | Pfizer |
| Information Provided By: | Pfizer |
| Last Update Posted: | 2026-10-14 |
Study Overview
Brief Summary
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Official Title
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
Conditions
Metastatic Castration-Resistant Prostate Cancer
Intervention / Treatment
- Drug: PF-06821497
- Drug: Placebo
- Drug: Enzalutamide
Other Study ID Numbers
- C2321003
- 2024-511652-40-00
Start Date (Actual)
2024-10-22
Primary Completion Date (Estimated)
2026-12-02
Study Completion Date (Estimated)
2028-11-30
Enrollment (Estimated)
900
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Pfizer |
| Information Provided By: | Pfizer |
| Last Update Posted: | 2026-10-14 |
Study Overview
Brief Summary
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Official Title
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
Conditions
Metastatic Castration-Resistant Prostate Cancer
Intervention / Treatment
- Drug: PF-06821497
- Drug: Placebo
- Drug: Enzalutamide
Other Study ID Numbers
- C2321003
- 2024-511652-40-00
Start Date (Actual)
2024-10-22
Primary Completion Date (Estimated)
2026-12-02
Study Completion Date (Estimated)
2028-11-30
Enrollment (Estimated)
900
Study Type
Interventional
Phase
Phase 3